PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
15.87%
Revenue growth under 50% of CRON.TO's 238.43%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
24.23%
Gross profit growth under 50% of CRON.TO's 580.65%. Michael Burry would be concerned about a severe competitive disadvantage.
40.42%
EBIT growth below 50% of CRON.TO's 301.37%. Michael Burry would suspect deeper competitive or cost structure issues.
40.42%
Operating income growth under 50% of CRON.TO's 621.43%. Michael Burry would be concerned about deeper cost or sales issues.
35321.48%
Net income growth above 1.5x CRON.TO's 713.40%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
15900.00%
EPS growth above 1.5x CRON.TO's 414.81%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
No Data
No Data available this quarter, please select a different quarter.
18.67%
Share reduction more than 1.5x CRON.TO's 95.51%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
-3.21%
Reduced diluted shares while CRON.TO is at 95.51%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
189.60%
OCF growth above 1.5x CRON.TO's 43.82%. David Dodd would confirm a clear edge in underlying cash generation.
78.29%
FCF growth above 1.5x CRON.TO's 2.09%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
425.89%
Positive long-term OCF/share growth while CRON.TO is negative. John Neff would see a structural advantage in sustained cash generation.
425.89%
Positive OCF/share growth while CRON.TO is negative. John Neff might see a comparative advantage in operational cash viability.
189.34%
Positive 3Y OCF/share CAGR while CRON.TO is negative. John Neff might see a big short-term edge in operational efficiency.
406.73%
Positive 10Y CAGR while CRON.TO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
406.73%
Positive 5Y CAGR while CRON.TO is negative. John Neff might view this as a strong mid-term relative advantage.
1531.95%
Positive short-term CAGR while CRON.TO is negative. John Neff would see a clear advantage in near-term profit trajectory.
340.60%
10Y equity/share CAGR above 1.5x CRON.TO's 1.10%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
340.60%
5Y equity/share CAGR above 1.5x CRON.TO's 1.10%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
407.04%
3Y equity/share CAGR above 1.5x CRON.TO's 1.10%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.97%
Firm’s AR is declining while CRON.TO shows 266.80%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
18.67%
Inventory shrinking or stable vs. CRON.TO's 49.71%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
28.78%
Asset growth above 1.5x CRON.TO's 5.94%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
10.83%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
-89.14%
Our R&D shrinks while CRON.TO invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
24.88%
SG&A declining or stable vs. CRON.TO's 97.50%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.